McKesson (MCK)
(Delayed Data from NYSE)
$595.73 USD
+5.74 (0.97%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $595.76 +0.03 (0.01%) 6:28 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$595.73 USD
+5.74 (0.97%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $595.76 +0.03 (0.01%) 6:28 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Zacks News
Thermo Fisher (TMO) to Offer Wheat & Sesame Allergy Testing
by Zacks Equity Research
Thermo Fisher's (TMO) ImmunoCAP blood tests receive FDA approval for wheat and sesame allergy diagnosis.
Here's Why You Should Buy ShockWave Medical (SWAV) Stock
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D efforts and commitment to clinical studies.
Here's Why You Should Hold on to NextGen (NXGN) Stock Now
by Zacks Equity Research
NextGen's (NXGN) solid product portfolio and continued demand for its solutions raise optimism about the stock.
Here's Why You Should Hold on to Catalent (CTLT) Stock Now
by Zacks Equity Research
Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism about the stock.
Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how argenex SE (ARGX) and McKesson (MCK) have performed compared to their sector so far this year.
Here's Why You Should Retain PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.
Here's Why You Should Retain Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to boost the top line further.
3 Reasons to Hold QuidelOrtho (QDEL) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its strong product portfolio.
Abiomed's (ABMD) Impella Favored by Latest Study Result
by Zacks Equity Research
Abiomed's (ABMD) Impella-supported high-risk PCI leads to significant improvements in cardiovascular patient outcomes, per latest study.
Zacks.com featured highlights TotalEnergies, ArcBest, Dollar General, McKesson and Archer-Daniels-Midland
by Zacks Equity Research
TotalEnergies, ArcBest, Dollar General, McKesson and Archer-Daniels-Midland have been highlighted in this Screen of The Week article.
West Pharmaceutical's (WST) Latest Investment to Boost Business
by Zacks Equity Research
West Pharmaceutical's (WST) minority investment is expected to aid in meeting patients' continuously evolving needs of ease of use and effective methods of medicine delivery.
Charles River (CRL) Business Hurt by Macro and FX Headwinds
by Zacks Equity Research
In Q2, the impact of foreign currency translation reduces Charles River's (CRL) reported revenue growth by 3.4%.
Dividend Growth Investing in Vogue: 5 Stock Picks
by Sweta Killa
Top-ranked dividend stocks like TotalEnergies (TTE), ArcBest (ARCB), Dollar General (DG), McKesson (MCK) and Archer-Daniels-Midland (ADM) are worth adding to your portfolio.
3 Reasons to Retain Ecolab (ECL) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Ecolab (ECL) owing to its solid product portfolio.
Are Investors Undervaluing AmerisourceBergen (ABC) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
McKesson's (MCK) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
McKesson's (MCK) fiscal first-quarter 2023 results benefit from segmental growth.
McKesson (MCK) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
McKesson (MCK) delivered earnings and revenue surprises of 9.79% and 5.14%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Is McKesson (MCK) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how McKesson (MCK) and argenex SE (ARGX) have performed compared to their sector so far this year.
The Zacks Analyst Blog Highlights McKesson, AmerisourceBergen, LHC Group and Glaukos
by Zacks Equity Research
McKesson, AmerisourceBergen, LHC Group and Glaukos are part of Zacks top Analyst Blog.
Medical Device Stocks' Earnings on Aug 3: MCK, ABC & More
by Indrajit Bandyopadhyay
Medical Device players are likely to have benefited from the reopening of economies and several efforts to combat staffing challenges. Let's see how MCK, ABC, LHCG and GKOS fare this time.
McKesson (MCK) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
McKesson's (MCK) fiscal first-quarter results are likely to reflect the solid show by the U.S. Pharmaceutical and Specialty Solutions segment.
McKesson (MCK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
McKesson (MCK) closed the most recent trading day at $340.12, moving +0.15% from the previous trading session.
Analysts Estimate Becton Dickinson (BDX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Align Technology (ALGN) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Align Technology (ALGN) delivered earnings and revenue surprises of -5.66% and 0.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate McKesson (MCK) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
McKesson (MCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.